September 13, 2019
BioPharma Credit in new investment deal
BioPharma Credit, the specialist life sciences debt investor, is in a senior secured note purchase agreement for the issuance and sale of senior secured notes in an aggregate original principal amount of up to $150 million by OptiNose US, Inc. alongside BioPharma Credit Investments, a private fund also investing in life sciences debt managed by Pharmakon Advisors launched in June 2019.
